This page lists the opinions drawn up by the Committee for Veterinary Medicinal Products (CVMP) under Article 141(1)(c) and Article 141(1)(e) of the Veterinary Medicinal Product Regulation on any scientific matter related to the evaluation of medicines for use in animals.

The Committee must draw up such an opinion at the request of the Executive Director of the European Medicines Agency or of the European Commission under Article 141(1)(c). It may also draw up an opinion following a request from a Member State under Article 141(1)(e).

Where the scientific issue concerns both human and veterinary medicines, the Committee may adopt a common opinion with the Committee for Medicinal Products for Human Use (CHMP).

Requests for this type of scientific opinion fall under Article 141(1)(c) and Article 141(1)(e) of Regulation (EU) No 2019/6 from January 2022.

Previously, this type of scientific opinion fell under Article 30(3) of Regulation (EC) No 726/2004.

For more information:

Dapsone as an impurity in veterinary medicinal products containing sulphamethoxazole or other sulphonamides

Histamine residues in veterinary medicinal products containing gentamicin for parental administration to horses

Potential risk for the consumer resulting from the use of lidocaine in food producing species

Retrovirus RD114 in live attenuated vaccines for use in animals

Risk for the consumer resulting from the use of diethanolamine as an excipient in veterinary medicinal products for food-producing species

Risks to vultures and other necrophagous bird populations in the Union in connection with the use of veterinary medicinal products containing the substance diclofenac

Topics

Share this page